Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Musk Heart Pill in Coronary Heart Disease with Critical Coronary Lesions and Type 2 Diabetes Mellitus
ChiCTR2500097605Phase 4Recruiting
- Sponsor
- Subei People's Hospital
- Start
- Mar 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Shexiang Baoxin Pill in coronary arteriosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Subei People's Hospital. Primary endpoints: Apelin-13 level and Major cardiovascular adverse events. Started Mar 2025; status: recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
coronary arteriosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500097605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097605.